ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 492

Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events

Sergio Schwartzman1, John Clark2 and John J. Cush3, 1Rheumatology, Hosp for Special Surgery, New York, NY, 2RiskBenefits LLC, Flourtown, PA, PA, 3Baylor Research Institute, Dallas, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, neurologic involvement and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose:  There are currently five anti-TNF agents that have been approved for various autoimmune illnesses.  There is no convincing evidence that any one of these is superior to the others in terms of efficacy. However, some differences in safety, such as tuberculosis risk, have been described.  There is no single source of information on the safety of these agents that is universally precise.  The Adverse Event Reporting System (AERS) maintained by the US Food and Drug Administration (FDA) receives spontaneous reports of adverse reactions to approved medications licensed for use in the United States. These are submitted by health care professionals or through the manufacturer. It is widely accepted that this type of reporting underestimates the number of actual cases of toxicity that occur and at times may be biased. Therefore any comparisons should be approached with caution. We sought to evaluate the frequency and type of neurologic events seen with TNF inhibitor (TNFi) therapy.

Methods: The AERS database was queried to identify neurological toxicity events following TNFi use reported from date of approval to end 2011 for etanercept, infliximab, adalimumab, golimumab and certolizumab.  The frequency of these events is influence by time and total market exposure for each agent. Groupings of preferred terms were used to retrieve the following adverse events: acoustic neuritis (AN), central demyelination other (CDO), chronic inflammatory demyelinating polyneuropathy (CIDP), demyelination NOS (DN), Guillain-Barre (GB), multiple sclerosis (MS), optic neuritis (ON), and peripheral neuropathy (PN). The results were calculated as report proportions, i.e. number of cumulative AE reports divided by number of cumulative total reports and expressed as percentages.

 

Results: The following cumulative report proportions were calculated from data received in AERS between the time of initial marketing through December 2011 (values in %).

 

Neurologic Event Reported

Etan

Infl

Adal

Goli

Cert

 

 

 

 

 

 

Acoustic Neuritis

0.00

0.00

0.00

0.00

0.00

Central Demyelination Other

0.00

0.00

0.00

0.00

0.00

Chronic Inflammatory Demyelinating Polyneuropathy

0.01

0.02

0.00

0.00

0.00

Demyelination NOS

0.12

0.36

0.10

0.00

0.07

Guillain Barre

0.04

0.17

0.06

0.00

0.01

Multiple Sclerosis

0.18

0.15

0.15

0.35

0.02

Optic Neuritis

0.08

0.14

0.06

0.12

0.08

Peripheral Neuropathy

0.20

0.41

0.17

0.00

0.20

 

 

 

 

 

 

Presumed Central Toxicity1

0.38

0.65

0.32

0.47

0.16

Presumed Peripheral Toxicity2

0.25

 

0.60

 

0.23

 

0.00

 

0.21

 

              1.   AN + CDO + DN + MS + ON              2. CIDP + GB + PN  

                    *All adverse events were coded using MedDRA; **NOS=Not Otherwise Specified.

 

Conclusion: From initial marketing in 1998 until December 31 2011 patients treated with different anti-TNF agents exhibited differing patterns of neurological injury. Compared to other anti-TNF agents, presumed central demyelination and conditions such as multiple sclerosis were less likely to be reported in patients receiving certolizumab.  The peripheral nerve events, Guillain-Barre and peripheral neuropathy, were more likely to be reported in patients receiving infliximab, as were non-specific terms that referred only to demyelination (DN). Golimumab had no peripheral neurological events, but had disproportionately more multiple sclerosis.  Although spontaneously reported data does not allow conclusions regarding causality, these results suggest that different anti-TNF agents may be associated with different rates of adverse neurological effects and with different sites of neurotoxicity within the nervous system.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

            

                   

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Disclosure:

S. Schwartzman,

Janssen, Abbott, UCB, Amgen, Pfizer, Genentech, Human Genome Science,

8;

J. Clark,
None;

J. J. Cush,

Genentch, Pfzer, UCB, Celgene, Amgen, Novartis, CORRONA, NIH,

2,

Jensen, Savient,Pfizer, BMS,Amgen, Genetech Abbott, UCB,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/divergent-toxicity-of-tnf-inhibitors-on-demyelinating-disorders-and-neurological-events/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology